In a three-arm randomised trial of MVA-BN, two intradermal doses of 2×10^7 TCID50 were non-inferior to standard subcutaneous dosing for day 43 neutralising antibody titres, but 1×10^7 was not; seroconversion was similarly high in all arms.
RCT
Frey et al. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination